#ESMO22: At five-year mark, Lynparza kept more patients alive than Avastin but missed overall OS significance

Kyle LaHucik

Senior Reporter

PARIS — AstraZeneca and Merck arrived at ESMO with long-term data on their blockbuster cancer drug and European confab staple Lynparza, which ushered in the PARP …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ESMO22: At five-year mark, Lynparza kept more patients alive than Avastin but missed overall OS significance

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

#ES­MO22: At five-year mark, Lyn­parza kept more pa­tients alive than Avastin but missed over­all OS sig­nif­i­cance

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

#ESMO22: At five-year mark, Lynparza kept more patients alive than Avastin but missed overall OS significance

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials